Browse > Article

Lorenzo's Oil Treatment in X-linked Adrenoleukodystrophy  

Kim, Hyo Jung (Department of Pediatrics, Kwangju Christian Hospital)
Kim, Eun Young (Department of Pediatrics, Kwangju Christian Hospital)
Woo, Young Jong (Department of Pediatrics Chonnam National University Medical School)
Kook, Hoon (Department of Pediatrics Chonnam National University Medical School)
Publication Information
Clinical and Experimental Pediatrics / v.48, no.11, 2005 , pp. 1232-1238 More about this Journal
Abstract
Purpose : Though more than 15 years have passed after introduction of Lorenzo's oil therapy in X-linked adrenoleukodystrophy(ALD), its efficacy is still fully not known. In patients who already have neurologic symptoms, most reports indicate that the neurologic disability continues to increase. We evaluated its efficacy in X-linked ALD patients. Methods : Four patients who were treated with Lorenzo's oil for at least 12 months were enrolled from 1996 to 2003. During treatment, changes of neurologic symptoms, brain magnetic resonance imaging(MRI) findings, and serum saturated very long-chain fatty acid(C26:0) were assessed. Results : Two patients with childhood cerebral ALD had progression of neurologic symptoms and MRI lesions during treatment. One asymptomatic patient developed childhood cerebral ALD after six year treatment of Lorenzo's oil. One "Addison only" patient remained neurologically intact after three years. During Lorenzo's oil therapy, serum C26:0 levels which had increased at diagnosis decreased in all four patients. Conclusion : Treatment with Lorenzo's oil did not prevent disease progression in childhood cerebral ALD patients who were already symptomatic. Long term follow up will be needed in asymptomatic ALD including "Addison only" to reveal the efficacy of Lorenzo's oil.
Keywords
Lorenzo's oil therapy; X-linked adrenoleukodystrophy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Uziel G, Bertini E, Bardelli P, Rimoldi M, Gambetti M. Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci 1991;13:274-9   DOI   ScienceOn
2 Moser HW, Moser AB, Smith KD, Bergin A, Borel J, Shankroff J, et al. Adrenoleukodystrophy : phenotypic variability and implications for therapy. J Inher Metab Dis 1992;15:645-64   DOI   ScienceOn
3 Rizzo WB, Phillips MW, Dammann AL, Leshner RT, Jennings SS, Avigan J, et al. Adrenoleukodystrophy : dietary oleic acid lowers hexacosanoate levels. Ann Neurol 1987;21: 232-9   DOI   ScienceOn
4 Janet B, Jannifer C. ALD-AMN diet cookbook. Sycamore : United Leukodystrophy Foundation, 1990:1-20
5 Aubourg P, Blanche S, Jambaque I, Rocchiccioli F, Kalifa G, Naud-Saudreau C, et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 1990;322:1860-6   DOI   ScienceOn
6 Shapiro E, Krivit W, Lockman L, Jambaque I, Peters C, Cowan M, et al. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 2000;356:713-8   DOI   ScienceOn
7 Stanislaus R, Pahan K, Singh AK, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett 1999;269:71-4   DOI   ScienceOn
8 Poulos A, Gibson R, Sharp P, Beckman K, Grattan-Smith P. Very long chain fatty acids in X-linked adrenoleu-kodystrophy brain after treatment with Lorenzo's oil. Ann Neurol 1994;36:741-6.   DOI   ScienceOn
9 Rizzo WB, Watkins PA, Phillips MW, Cranin D, Campbell B, Avigan J. Adrenoleukodystrophy : oleic acid lowers fibroblast saturated C22-26 fatty acids. Neurology 1986;36:357- 61   DOI
10 Brown FR 3rd, van Duyn MA, Moser AB, Schulman JD, Rizzo WB, Snyder RD, et al. Adrenoleukodystrophy : effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids. Johns Hopkins Med J 1982;151: 164-72
11 Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adrenoleukodystrophy : cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 1992;51:630-43   DOI   PUBMED
12 Moser HW, Smith KD, Watkins PA, Powers J, Moser AB. X-linked adrenoleukodystrophy. In : Scriver CR, Beaudet AL, editors. The metabolic & molecular bases of inherited disease. 8th ed. New York : McGraw-Hill company, 2001: 3257-301
13 Odone A, Odone M. Lorenzo's oil : a new treatment for adrenoleukodystrophy. J Pediatr Neurosci 1989;5:55-61   DOI   ScienceOn
14 Singh I, Pahan K, Kahn M. Lovastatin and sodium phenylacetate normalize the levels of very-long-chain fatty acids in skin fibroblasts of X-adrenoleukodystrophy. FEBS Lett 1998;426:342-6   DOI   ScienceOn
15 Rizzo WB, Leshner RT, Odone A, Damman AL, Craft DA, Jensone ME, et al. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 1989;39:1415-22   DOI
16 Bourre JM, Daudu O, Baumann N. Nervonic acid biosynthesis by erucyl-coA elongation in normal and quaking mouse brain microsomes. Elongation of other unsaturated fatty acyl-coAs(mono and polyunsaturated). Biochim Biophys Acta 1976;424:1-7   DOI   ScienceOn
17 Korenke GC, Hunneman DH, Kohler J, StOckler S, Landmark K, Hanefeld F. Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/ adrenomyeloneuropathy : effect on clinical, biochemical, and neurophysiological parameters. Eur J Pediatr 1995; 154:64-70   DOI   ScienceOn
18 Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol 1999;12:167-76   DOI   ScienceOn
19 Moser HW, Borel J. Dietary management of X-linked adrenoleukodystrophy. Annu Rev Nutr 1995;15:379-97   DOI   ScienceOn
20 Weinhofer I, Forss-Petter S, Zigman M, Berger J. Cholesterol regulates ABCD2 expression : implications for the therapy of X-linked adrenoleukodystrophy. Hum Mol Genet 2002;11:2701-8   DOI   ScienceOn
21 Koc ON, Day J, Nieder M, Gerson SL, Luzarus HM, Krivit W. Allogenic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy(MLD) and Hurler syndrome( MPS-IH). Bone Marrow Transplant 2002;30:215-22.   DOI   ScienceOn
22 Asano J, Sujuki Y, Yajima S, Inoue K, Shimozawa N, Kondo N, et al. Effects of erucic acid therapy on Japanese patients with X-linked adrenoleukodystrophy. Brain Dev 1994;16:454-8   DOI   ScienceOn
23 Moser HW, Fatemi A, Zackowski K, Smith S, Golay X, Muenz L, et al. Evaluation of therapy of X-linked adrenoleukodystrophy. Neurochem Res 2004;29:1003-16   DOI   ScienceOn
24 Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, Rocchiccioli F, Cartier N, Jambaque I, et al. A two-year trial of oleic acid and erucic acids('Lorenzo's oil') as treatment for adrenomyeloneuropathy. N Engl J Med 1993;329:745-52.   DOI   ScienceOn
25 Moser HW. Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy. J Neuropathol Exp Neurol 1995;54:740-5   DOI   PUBMED   ScienceOn
26 Van Geel BM, Assies J, Haverkort EB, Koelman JH, Verbeeten B Jr, Wanders RJ, et al. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with 'Lorenzo's oil'. J Neurol Neurosurg Psychiat 1999;67: 290-9   DOI